Can Fite Biopharma Ltd Market Cap ($2.95 Million)
Market Cap & Net Worth: Can Fite Biopharma Ltd (CANF)
Can Fite Biopharma Ltd market cap. Can Fite Biopharma Ltd (TA:CANF) has a market capitalization of $2.95 Million (ILA1.10 Billion) as of October 31, 2026. Listed on the TA stock exchange, this Israel-based company holds position #29497 globally and #425 in its home market, demonstrating a -15.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Can Fite Biopharma Ltd's stock price ILA257.00 by its total outstanding shares 4285093 (4.29 Million).
Can Fite Biopharma Ltd Market Cap History (2015–2026)
Can Fite Biopharma Ltd market cap history from 2015 to 2026. Data shows change from $6.58 Million to $2.95 Million (-9.61% CAGR). Check CANF share price today for real-time trading data and today's change.
Can Fite Biopharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Can Fite Biopharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see CANF cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.03x
Can Fite Biopharma Ltd's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $5.17 Million | $169.50K | -$6.90 Million | 30.50x | N/A |
| 2017 | $2.88 Million | $844.75K | -$4.97 Million | 3.40x | N/A |
| 2018 | $2.67 Million | $3.82 Million | -$6.57 Million | 0.70x | N/A |
| 2019 | $426.21K | $2.03 Million | -$12.62 Million | 0.21x | N/A |
| 2020 | $227.47K | $763.00K | -$14.44 Million | 0.30x | N/A |
| 2021 | $170.03K | $853.00K | -$12.60 Million | 0.20x | N/A |
| 2022 | $96.50K | $810.00K | -$10.17 Million | 0.12x | N/A |
| 2023 | $29.87K | $743.00K | -$7.63 Million | 0.04x | N/A |
| 2024 | $21.83K | $674.00K | -$7.88 Million | 0.03x | N/A |
| 2025 | $11.49K | $438.40K | -$10.64 Million | 0.03x | N/A |
Competitor Companies of CANF by Market Capitalization
Companies near Can Fite Biopharma Ltd in the global market cap rankings as of October 31, 2026. See CANF equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to Can Fite Biopharma Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Can Fite Biopharma Ltd (2015–2026)
Market capitalization of Can Fite Biopharma Ltd from 2015 to today. Between 2015 and today, Can Fite Biopharma Ltd's market cap moved from $6.58 Million to $ 2.95 Million, with a yearly change of -9.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA2.95 Million | +25600.00% |
| 2025 | ILA11.49K | -47.37% |
| 2024 | ILA21.83K | -26.92% |
| 2023 | ILA29.87K | -69.05% |
| 2022 | ILA96.50K | -43.24% |
| 2021 | ILA170.03K | -25.25% |
| 2020 | ILA227.47K | -46.63% |
| 2019 | ILA426.21K | -84.04% |
| 2018 | ILA2.67 Million | -7.11% |
| 2017 | ILA2.88 Million | -44.38% |
| 2016 | ILA5.17 Million | -21.38% |
| 2015 | ILA6.58 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Can Fite Biopharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.95 Million USD |
| MoneyControl | $2.95 Million USD |
| MarketWatch | $2.95 Million USD |
| marketcap.company | $2.95 Million USD |
| Reuters | $2.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Can Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more